Fang P, et al. - In this investigation, researchers assessed the recent transformation of end-of-life (EOL) chemotherapy and targeted therapy practices nationally. They assessed the guideline-benchmarked measure of chemotherapy use within 14 days of EOL in SEER-Medicare in patients older than 65 years of age who died as a result of breast (n = 19,887), lung (n = 79,613), colorectal (n = 29,844), or prostate (n = 17,910) cancer between 2007 and 2013. With national benchmarking, chemotherapy declined to less than 5% within 14 days of EOL, with physicians taking up a comprehensive benchmark. Outcomes can inform current strategies to help achieve high-value practice of EOL oncology.